Cas No.: | 1229022-83-6 |
pH value: | Corresponds to reference standard: PASS |
Non-reduced CE-SDS: | 98.8% |
SEC-HPLC: | 99.1% |
Isoelectric Point: | Corresponds to reference standard:PASS |
Bacterial Endotoxins Test: | <1 EU/ml |
Exogenous Residual DNA: | <1 pg/mg |
Residual protein A: | <1 ng/mg |
Biological Activity: | Compared with standard, the range of biological activity is 112% |
Osmolality: | Corresponds to reference standard: PASS |
Peptide mapping: | Corresponds to reference standard: PASS |
N-terminal sequence: | Corresponds to reference standard:PASS |
Description: | Secukinumab is a fully human immunoglobulin G1-kappa monoclonal antibody that directly inhibits interleukin (IL)-17A, has been shown to have robust efficacy in the treatment of moderate-to-severe psoriasis (PsO), psoriatic arthritis (PsA), and ankylosing |